Form 4: Bionano Genomics Executive Reports Share Withholding for Tax Obligations and Impact of Stock Split

Mark Adamchak, Principal Accounting Officer at Bionano Genomics, reports the withholding of shares to cover tax obligations related to vested RSUs and the impact of a prior stock split.

Summary

• On February 15, 2025, Bionano Genomics withheld 4 shares of common stock from Mark Adamchak, the Principal Accounting Officer, to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs) granted on February 15, 2023.
• The shares were withheld at a price of $5.73 per share.
• A 1-for-60 stock split on January 24, 2025, resulted in Adamchak owning 16,197 fewer shares.
• Following these transactions, Adamchak directly owns 270 shares of Bionano Genomics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions related to an executive's compensation and a stock split. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock adjustments, common in publicly traded companies. It provides transparency into insider transactions and helps investors understand the ownership structure of Bionano Genomics.

Stakeholder Impact

• The stock split may have a minor impact on shareholders by adjusting the number of shares they own, but the overall value of their holdings should remain relatively unchanged.
• The tax withholding impacts the executive's net compensation from the RSU vesting.

Key Dates

Keywords

Bionano Genomics, BNGO, Form 4, Insider Trading, Stock Split, RSU, Tax Withholding, Mark Adamchak, Principal Accounting Officer